High-quality supportive care.

Evaluate for curative approaches; allogeneic stem cell transplantation (could include intermediate-1 risk)

Hypomethylating agents, if available or in clinical trials

Evaluate for clinical trials with new therapies

Evaluate for induction chemotherapy (individual risk analysis based on performance status, and probability of response)

Evaluate for low-dose chemotherapy